CM - yes agreed, especially about the need for robust clinical data. Unfortunately, as we know from the last few years, this is very costly and slow. Onc is only getting enough cash for the next year or so, and thus is always going to be pushed financially. Where does the cash come from to expand and speed up the clinical trials?
OSL Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)